[an error occurred while processing this directive]

高等学校化学研究 ›› 2024, Vol. 40 ›› Issue (4): 564-576.doi: 10.1007/s40242-024-4053-1

• Reviews • 上一篇    下一篇

Nanotechnology-based Detection Strategies for Hypertension Biomarkers

WANG Zhichao1,2, ZENG Yuan2, WANG Yaling2, CHEN Chunying2   

  1. 1. Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, P. R. China;
    2. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Chinese Academy of Sciences (CAS), Beijing 100190, P. R. China
  • 收稿日期:2024-03-02 出版日期:2024-08-01 发布日期:2024-07-24
  • 通讯作者: CHEN Chunying,chenchy@nanoctr.cn;WANG Yaling,wangyl@nanoctr.cn E-mail:chenchy@nanoctr.cn;wangyl@nanoctr.cn
  • 基金资助:
    This work was supported by the National Natural Science Foundation of China (Nos. 22307028, 82341044, 22027810). the National Basic Research Program of China (Nos. 2022YFA1603701, 2021YFA1200900), the Strategic Priority Research Program of Chinese Academy of Sciences (No. XDB36000000), and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. CIFMS 2019-I2M-5-018).

Nanotechnology-based Detection Strategies for Hypertension Biomarkers

WANG Zhichao1,2, ZENG Yuan2, WANG Yaling2, CHEN Chunying2   

  1. 1. Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, P. R. China;
    2. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Chinese Academy of Sciences (CAS), Beijing 100190, P. R. China
  • Received:2024-03-02 Online:2024-08-01 Published:2024-07-24
  • Contact: CHEN Chunying,chenchy@nanoctr.cn;WANG Yaling,wangyl@nanoctr.cn E-mail:chenchy@nanoctr.cn;wangyl@nanoctr.cn
  • Supported by:
    This work was supported by the National Natural Science Foundation of China (Nos. 22307028, 82341044, 22027810). the National Basic Research Program of China (Nos. 2022YFA1603701, 2021YFA1200900), the Strategic Priority Research Program of Chinese Academy of Sciences (No. XDB36000000), and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. CIFMS 2019-I2M-5-018).

摘要: Hypertension significantly increases the risk of cardiovascular diseases and seriously affects people’s health. The incidence of hypertension is rising rapidly in the world and hypertension has become a significant factor influencing the global average life expectancy. The diagnosis of hypertension is generally fulfilled by measuring diastolic and systolic blood pressure, but it is insufficient to differentiate essential hypertension from secondary hypertension, so it is crucial to identifying the cause of hypertension by detecting biomarkers in plasma. In clinical practice, five plasma biomarkers are utilized for diagnosing hypertension, and the detection tasks of a large number of cases have raised increasing demands for cost-effective, efficient, speedy, and diverse methods, which makes many traditional diagnostic technologies inadequate for meeting the needs of clinical diagnosis. The nanomaterial-based detection techniques have frequently attained the qualities of quick reaction, low cost, straightforward operation, high sensitivity, and strong specificity in recent years with the advancement of nanotechnology, so they have great potential for early and rapid diagnosis. In this review, we will introduce the characteristics and drawbacks of current clinical detection methods for hypertension screening, the principles and advancements of nanotechnology-based detection methods, as well as their potentials for clinical application.

关键词: Hypertension, Biomarker, Diagnosis, Clinical detection, Nanotechnology-based detection

Abstract: Hypertension significantly increases the risk of cardiovascular diseases and seriously affects people’s health. The incidence of hypertension is rising rapidly in the world and hypertension has become a significant factor influencing the global average life expectancy. The diagnosis of hypertension is generally fulfilled by measuring diastolic and systolic blood pressure, but it is insufficient to differentiate essential hypertension from secondary hypertension, so it is crucial to identifying the cause of hypertension by detecting biomarkers in plasma. In clinical practice, five plasma biomarkers are utilized for diagnosing hypertension, and the detection tasks of a large number of cases have raised increasing demands for cost-effective, efficient, speedy, and diverse methods, which makes many traditional diagnostic technologies inadequate for meeting the needs of clinical diagnosis. The nanomaterial-based detection techniques have frequently attained the qualities of quick reaction, low cost, straightforward operation, high sensitivity, and strong specificity in recent years with the advancement of nanotechnology, so they have great potential for early and rapid diagnosis. In this review, we will introduce the characteristics and drawbacks of current clinical detection methods for hypertension screening, the principles and advancements of nanotechnology-based detection methods, as well as their potentials for clinical application.

Key words: Hypertension, Biomarker, Diagnosis, Clinical detection, Nanotechnology-based detection